LTR Pharma Limited (ASX:LTP) Signs Collaborative Agreement for OROFLOW® Development
Collaborative Development Agreement
LTR Pharma Limited (ASX:LTP) has entered into a development agreement with Strategic Drug Solutions, Inc. (SDS) to co-develop OROFLOW®, an intranasal spray targeting Oesophageal Motility Disorders (OMD). The program will initiate Proof-of-Concept testing in the coming months, aiming to provide rapid symptom relief within approximately ten minutes.
Market Opportunity
The global market for OMD treatment is valued at $4.5 billion in 2024 and is projected to reach $8.1 billion by 2034. Growth is driven by increasing prevalence, better diagnostic capabilities, and expanded access to advanced treatments. The United States leads the market with $1.94 billion, followed by significant opportunities in East Asia.
Executive Comments
Executive Chairman Lee Rodne stated, “OROFLOW represents an exciting expansion of our nasal spray platform. For patients with swallowing difficulties, oral medications present obvious challenges. Our nasal spray technology offers a patient-friendly solution that avoids the need to swallow medications, have surgery, or undergo other problematic treatments while providing rapid symptom relief.”
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
